National Pharmaceutical Pricing Authority (NPPA) Regulatory Services
At Regalliance, our team brings years of cumulative regulatory expertise in navigating India’s pharmaceutical legal framework. Commercializing pharmaceutical products in India extends beyond CDSCO clinical and manufacturing approvals—it requires strict, continuous compliance with national price control mandates.
National Pharmaceutical Pricing Authority (NPPA) Regulatory Services
At Regalliance, our team brings years of cumulative regulatory expertise in navigating India’s pharmaceutical legal framework. Commercializing pharmaceutical products in India extends beyond CDSCO clinical and manufacturing approvals—it requires strict, continuous compliance with national price control mandates.
Introduction
The National Pharmaceutical Pricing Authority (NPPA), an autonomous organization under the Department of Pharmaceuticals (Ministry of Chemicals & Fertilizers), enforces the Drugs (Prices Control) Order, 2013 (DPCO, 2013) under the Essential Commodities Act, 1955. Whether you are launching a scheduled formulation, introducing a new drug variant, or managing non-scheduled product lines, Regalliance provides end-to-end price compliance, IPDMS 2.0 portal management, and strategic overcharge risk mitigation.
Strategic NPPA Compliance Frameworks
Under the DPCO 2013 framework, all pharmaceutical products distributed, manufactured, or imported into India fall under distinct regulatory price regimes:
1. Scheduled Formulations (Schedule-I / NLEM)
Formulations listed under Schedule-I of DPCO 2013 (derived from the National List of Essential Medicines – NLEM) are subject to mandatory Ceiling Price Caps fixed by the NPPA.
Annual Price Adjustments: Ceiling prices are revised annually based on the Wholesale Price Index (WPI) for the preceding calendar year.
Mandatory Compliance: No company can sell a scheduled drug above the notified ceiling price plus actual local taxes paid.
2. Retail Price Approval for "New Drugs" [Para 2(1)(u)]
A “New Drug” under DPCO 2013 refers to any formulation launched by combining an existing NLEM medicine with another drug, or by changing its strength, dosage, or route of administration.
Prior Approval Requirement: Existing or new manufacturers/marketers cannot launch a “New Drug” without obtaining explicit prior retail price approval from the NPPA via Form I filings.
3. Non-Scheduled Formulations (10% Annual Cap Management)
For medicines not listed in Schedule-I (branded or generic):
Price Monitoring: Manufacturers are legally restricted from increasing the Maximum Retail Price (MRP) by more than 10% within any 12-month period.
Overcharge Monitoring: NPPA actively audits market prices, and any price hike exceeding 10% per annum triggers overcharge recovery proceedings with compound interest.
Core NPPA Regulatory Services Offered by Regalliance
1. NPPA Pricing & IPDMS Compliance
1. IPDMS 2.0 Portal Registration & Account Setup
2. Mandatory Statutory Form Filings
| Statutory Form | Purpose | Requirement & Timeline |
|---|---|---|
| Form I | Application for Price Approval of New Drug | Mandatory prior approval before launching a new dosage strength, combination, or delivery form of an NLEM scheduled drug. |
| Form II | Submission of Revised Price List | Updated price lists must be submitted whenever ceiling prices or annual WPI revisions are notified by NPPA. |
| Form III | Quarterly Production & Import Returns | Mandatory quarterly reporting of production, imports, sales volumes, and price-to-retailer (PTR) details for scheduled formulations. |
| Form IV | Discontinuation of Production | Mandatory submission at least six months before discontinuing manufacture or import of a scheduled formulation. |
| Form V | Price List to Dealers & Retailers | Mandatory issuance and display of price lists for scheduled and non-scheduled formulations supplied through the distribution chain. |
3. Price Fixation & Price Revision Filings
4. Overcharge Notice Defense & Query Resolution
Why Choose Regalliance?
Partner with Regalliance for Complete NPPA Compliance
Frequently Asked Questions (FAQs)
Frequently Asked Questions
Q1: What is the role of the National Pharmaceutical Pricing Authority (NPPA)?
NPPA regulates the prices of scheduled medicines under the Drugs (Prices Control) Order (DPCO), 2013, monitors the prices of non-scheduled drugs, and ensures the availability and affordability of essential medicines across India.
Q2: Who must register on the IPDMS 2.0 portal?
All pharmaceutical manufacturers, importers, marketers, brand owners, loan license holders, and Authorized Indian Agents involved in regulated pharmaceutical products must register and maintain updated records on the IPDMS 2.0 portal.
Q3: What is Form I under DPCO 2013?
Form I is the statutory application submitted to NPPA for obtaining prior price approval before launching a new dosage strength, formulation, or combination of a scheduled medicine covered under the National List of Essential Medicines (NLEM).
Q4: When should Form II be submitted?
Form II must be filed whenever NPPA notifies a revised ceiling price or annual Wholesale Price Index (WPI) revision, requiring manufacturers to issue updated price lists for scheduled formulations.
Q5: What information is reported in Form III?
Form III requires quarterly reporting of production quantities, imports, sales volumes, price-to-retailer (PTR) details, and other statutory information for scheduled pharmaceutical formulations.
Q6: When is Form IV mandatory?
Form IV must be submitted to NPPA at least six months before discontinuing the manufacture or import of any scheduled formulation to ensure uninterrupted public availability of essential medicines.
Q7: What is the annual price increase limit for non-scheduled drugs?
Under DPCO 2013, manufacturers of non-scheduled formulations cannot increase the Maximum Retail Price (MRP) by more than 10% during any twelve-month period unless otherwise permitted by applicable regulations.
Q8: What happens if a company charges above the NPPA ceiling price?
NPPA may initiate overcharge recovery proceedings requiring repayment of the excess amount collected along with applicable interest and may issue Show Cause Notices under the Essential Commodities Act, 1955.
Q9: Can manufacturers apply for a special price revision?
Yes. Manufacturers may apply to NPPA for price revision under Paragraph 19 of DPCO 2013 in exceptional circumstances involving public interest or other justified grounds supported by appropriate documentation.
Q10: How does Regalliance assist with NPPA compliance?
Regalliance provides end-to-end NPPA compliance services including IPDMS 2.0 registration, statutory Form I–V filings, price approval applications, WPI revision implementation, overcharge notice representation, regulatory audits, and ongoing DPCO compliance support.